|
rs944289
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Association of rs944289, which was previously known to confer risk for thyroid cancer, with FA, and the correlation between PTCSC3 and NRG1 expression demonstrates that predisposing genetic factors are partly common for benign and malignant thyroid tumors, and imply broader roles of the pathways they underlie in thyroid tumorigenesis, not limited to carcinogenesis.
|
25562676 |
2015 |
|
rs944289
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Five single nucleotide polymorphisms (SNPs) associated with thyroid cancer (TC) risk have been reported: rs2910164 (5q24); rs6983267 (8q24); rs965513 and rs1867277 (9q22); and rs944289 (14q13).
|
22282540 |
2012 |
|
rs944289
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Overall, meta-analysis of rs944289</span> showed 1.11-fold increased risk of thyroid cancer related to the risk T allele (T vs. C: OR 1.11, 95 % CI 1.05-1.17).
|
26206751 |
2015 |
|
rs944289
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Our result demonstrated that rs9442</span>89 polymorphism on 14q13.3 is a low penetrant risk factor for developing TC.
|
25552255 |
2015 |
|
rs944289
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Five single nucleotide polymorphisms (SNPs) were previously reported to be associated with thyroid cancer in European populations in two genome-wide association studies (GWAS): rs965513 (9q22.33), rs944289 (14q13.3), rs116909374 (14q13.3), rs966423 (2q35) and rs2439302 (8p12).
|
23847140 |
2013 |
|
rs116909374
|
|
|
0.040 |
GeneticVariation |
BEFREE |
We found that four SNPs were significantly associated with thyroid cancer in Han Chinese population, while no polymorphism was observed for rs116909374.
|
24591304 |
2014 |
|
rs116909374
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Five single nucleotide polymorphisms (SNPs) were previously reported to be associated with thyroid cancer in European populations in two genome-wide association studies (GWAS): rs965513 (9q22.33), rs944289 (14q13.3), rs116909374 (14q13.3), rs966423 (2q35) and rs2439302 (8p12).
|
23847140 |
2013 |
|
rs116909374
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Recent genome-wide association (GWA) and candidate studies identified 6 single nucleotide polymorphisms (SNPs; rs966423, rs2439302, rs965513, rs6983267, rs944289, and rs116909374), associated with increased TC risk in Europeans but their effects on disease risk have not been comprehensively tested in Hispanics.
|
27512836 |
2016 |
|
rs116909374
|
|
|
0.040 |
GeneticVariation |
BEFREE |
After combining the results, three variants were shown to associate with thyroid cancer: rs966423 on 2q35 (OR = 1.34; P(combined) = 1.3 × 10(-9)), rs2439302 on 8p12 (OR = 1.36; P(combined) = 2.0 × 10(-9)) and rs116909374 on 14q13.3 (OR = 2.09; P(combined) = 4.6 × 10(-11)), a region previously reported to contain an uncorrelated variant conferring risk of thyroid cancer.
|
22267200 |
2012 |
|
rs2145418
|
|
|
0.010 |
GeneticVariation |
BEFREE |
A statistically significant association between thyroid cancer incidence and the rs2145418 and rs4658973 polymorphisms was found (P < 0.0001).
|
18559567 |
2008 |
|
rs6013897
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Genetic variants close to genes that encode crucial enzymes for the synthesis (<i>DHCR7</i> rs12785878), metabolism (<i>CYP2R1</i> rs2060793) and degradation (<i>CYP24A1</i> rs6013897) of vitamin D have been associated with serum levels of vitamin D. The aim of this case-control study was to determine the effect of these variants in the vitamin D pathway on the susceptibility to thyroid cancer.
|
31357732 |
2019 |
|
rs907580
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The genetic susceptibility of thyroid cancer seems likely to be associated with the risk allele at rs944289 in the TITF1 gene and at rs1867277, rs965513, rs1443434, and rs907580 in the TITF2 gene.
|
26206751 |
2015 |
|
rs2241880
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Recently, a non-synonymous single-nucleotide polymorphism in ATG16L1 (Thr300Ala), previously identified as a risk factor in Crohn's disease (CD), was associated with more favourable clinical outcomes in thyroid cancer.
|
25645662 |
2016 |
|
rs1064795638
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In addition, family members harboring the BAP1 c.1777C>T germline mutation developed other neoplastic disease including thyroid cancer.
|
26774355 |
2016 |
|
rs121913364
|
|
|
0.710 |
GeneticVariation |
BEFREE |
Histopathologic and Clinical Characterization of Thyroid Tumors Carrying the BRAF(K601E) Mutation.
|
26422023 |
2016 |
|
rs121913364
|
|
C |
0.710 |
GeneticVariation |
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
|
rs121913365
|
|
G |
0.700 |
GeneticVariation |
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
|
rs397507484
|
|
G |
0.700 |
GeneticVariation |
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Thus, regulation of AMPK activity may be potentially useful as a therapy for th</span>yroid cancer</span> if the cancer harbors a BRAF V600E mutation.
|
21795305 |
2011 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Investigating BRAF((V600E)) inhibitors (BRAFi) as a strategy to treat patients with aggressive thyroid tumors harboring the BRAF((V600E)) mutant currently is in progress, and drug resistance is expected to pose a challenge.
|
26456124 |
2016 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Expression of haem oxygenase-1 correlates with tumour aggressiveness and BRAF V600E expression in thyroid cancer.
|
25262966 |
2015 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Notch functions as an oncogene or tumor suppressor according to the type of malignancy, and the BRAF(V600E) mutation is commonly observed in thyroid cancer.
|
22118425 |
2012 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In conclusion, our study showed a high implication of TSHR gene methylation and its significant association with BRAF V600E mutation in thyroid tumors, depicting a positive connection between TSHR pathway and MAP Kinase pathway.
|
24927793 |
2014 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
It is evident that the detection of the BRAF V600E mutation is crucial in order to identify novel avenues for thyroid cancer treatment.
|
22858857 |
2012 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
After treatment with the potent MEK 1/2 inhibitor AZD6244, MEK inhibition and cell growth were examined in four BRAF mutant (V600E) and two BRAF wild-type thyroid cancer cell lines and in xenografts from a BRAF mutant cell line.
|
17878251 |
2007 |